Boston Partners
PTCT icon

Boston Partners’s PTC Therapeutics PTCT Stock Holding History

Boston Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.6M Buy
718,574
+71,092
+11% +$5.13M 0.05% 258
2026
Q1 		$44.1M Buy
647,482
+159,505
+33% +$11.3M 0.05% 271
2025
Q4 		$37.1M Buy
487,977
+126,313
+35% +$9.18M 0.04% 294
2025
Q3 		$22.2M Buy
+361,664
New +$18.8M 0.02% 361

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boston Partners's PTCT Position: Q2 2026 in Review

Boston Partners increased its PTC Therapeutics (PTCT) stake by 11% in Q2 2026, buying an estimated $5.13M and bringing the position to 718,574 shares worth $58.6M. The position accounts for 0.05% of the portfolio, ranked #258.

Boston Partners first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. 236 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Boston Partners held 718,574 shares of PTC Therapeutics worth $58.6M as of Q2 2026.
  • Boston Partners bought 71,092 PTC Therapeutics shares in Q2 2026, an estimated $5.13M.
  • PTC Therapeutics made up 0.05% of Boston Partners's portfolio in Q2 2026, its #258 holding.
  • Boston Partners first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 236 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.